https://www.abc.net.au/news/2020-07-17/coronavirus-update-covid19...

https://www.abc.net.au/news/2020-07-17/coronavirus-update-covid19--inflammatory-condition-coronavirus/12464608

"A Centers for Disease Control and Prevention says 342 US children and teens have developed a serious inflammatory condition linked to COVID-19. Dr Ermias Belay says the average age among cases was eight and most cases were in children aged between one and 14. One in four affected children were put on ventilators, but deaths have been rare. The condition — multisystem inflammatory syndrome — is rare but can occur in children with current or recent COVID-19 infections. Symptoms include fever and problems in at least two organs,often including the heart. Digestive problems are common, and some cases have been mistaken with Kawasaki disease and toxic shock syndrome."

Survival is one thing, being effectively treated for COVID so you are as healthy and free from ongoing organ issues after survival is another. IMO, we still don't know enough about the longer term detrimental effects of COVID on the human body. This multisystem inflammatory syndrome in children, IMO, provides an insight into the longer term impacts of COVID.

Our expanded access protocol (EAP) has been initiated on July 6 2020 in the United States for compassionate use of our allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L in the treatment of COVID-19 infected children with cardiovascular and other complications of multisystem inflammatory syndrome (MIS-C).

I am very keen to see the results of the inflammatory markers for the 50 children to be treated as part of the EAP. I believe this data will demonstrate the effectiveness of Rem-L on taming the inflammatory response of COVID (MIS-C).

This EAP hasn't happened by accident, this a deliberate step taken by the FDA and Mesoblast to yet again demonstrate the healing and regenerative capabilities of Rem-L on inflammatory disease and opens the door to a label extension for Rem-L for the treatment of children with MIS-C, when, IMO, Rem-L is approved for use for both (SR-aGVHD) in children and COVID-19 ARDS.

GLTAB